Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - United Kingdom: Northern Ireland

SAFETY DATA SHEET



TEKNOCOAT AQUA 1878-63 - HY 0030 CLEAR

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1	Product	identifier
-----	---------	------------

Product name : TEKNOCOAT AQUA 1878-63 - HY 0030 CLEAR

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

```
responsible for this SDS
```

National contact

Teknos Ireland Limited, 52 Ballymoughan Road, Magherafelt, BT45 6HN, UK. Tel. +44 (0) 2879 301 472.

1.4 Emergency telephone number

National advisory body/Poison Centre

Telephone number : NHS: 111

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture <u>Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]</u> Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended. See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements		
Signal word	1	No signal word.
Hazard statements	1	No known significant effects or critical hazards.
Precautionary statements		
Prevention	1	Not applicable.
Response	1	Not applicable.
Storage	1	Not applicable.
Disposal	1	Not applicable.
Supplemental label elements	:	Contains adipohydrazide, 1,2-benzisothiazol-3(2H)-one and reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1). May produce an allergic reaction. Safety data sheet available on request.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	

2.3 Other hazards

SECTION 2: Hazards identification

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do : None known. not result in classification

SECTION 3: Composition/information on ingredients

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
ℬ-Butoxypropan-2-ol	REACH #: 01-2119475527-28 EC: 225-878-4 CAS: 5131-66-8 Index: 603-052-00-8	≤3	Skin Irrit. 2, H315 Eye Irrit. 2, H319	-	[1]
adipohydrazide	REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8	<1	Skin Sens. 1, H317 Aquatic Chronic 2, H411	-	[1]
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.036	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	ATE [Oral] = 450 mg/kg ATE [Inhalation (dusts and mists)] = 0.21 mg/l Skin Sens. 1, H317: C $\ge 0.036\%$ M [Acute] = 1 M [Chronic] = 1	[1]
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3:1)	EC: 911-418-6 CAS: 55965-84-9 Index: 613-167-00-5	<0.0015	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 53 mg/ kg ATE [Dermal] = 50 mg/kg ATE [Inhalation (vapours)] = 0.5 mg/l Skin Corr. 1C, H314: $C \ge 0.6\%$ Eye Dam. 1, H318: $C \ge 0.6\%$ Eye Irrit. 2, H319: $0.06\% \le C < 0.6\%$ Skin Sens. 1, H317: $C \ge 0.0015\%$ M [Acute] = 100 M [Chronic] = 100	[1]
			See Section 16 for the full text of the H statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. <u>Type</u>

[1] Substance classified with a health or environmental hazard

Occupational exposure limits, if available, are listed in Section 8.

:06/10/2023

SECTION 4: First aid measures

4.1 Description of first aid n	neasures
Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Skin contact	 Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
Ingestion	: Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/symptoms				
Eye contact	: No specific data.			
Inhalation	: No specific data.			
Skin contact	: No specific data.			
Ingestion	: No specific data.			

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media		
Suitable extinguishing media	:	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising f	rom	the substance or mixture
Hazards from the substance or mixture	:	In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	:	Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides
5.3 Advice for firefighters		
Special protective actions for fire-fighters	:	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	:	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	tective equipment and emergency procedures
For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
For emergency responders	: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and material for	containment and cleaning up
Small spill	: Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits		
Product/ingredient name		Exposure limit values
No exposure limit value known.		
Biological exposure indices		
Product/ingredient	name	Exposure indices
No exposure indices known.		
Recommended monitoring : procedures	European Stand assessment of e values and mea atmospheres - C of exposure to c (Workplace atm for the measure	Id be made to monitoring standards, such as the following: lard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit surement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment themical and biological agents) European Standard EN 482 ospheres - General requirements for the performance of procedures ment of chemical agents) Reference to national guidance nethods for the determination of hazardous substances will also be
DNELs/DMELs		
Product/ingredient name		Result
₿-Butoxypropan-2-ol		DNEL - General population - Long term - Oral 12.5 mg/kg bw/day <u>Effects</u> : Systemic
		DNEL - General population - Long term - Dermal 22 mg/kg bw/day <u>Effects</u> : Systemic
		DNEL - General population - Long term - Inhalation 43 mg/m ³ Effects: Systemic
		DNEL - Workers - Long term - Dermal 52 mg/kg bw/day <u>Effects</u> : Systemic
		DNEL - Workers - Long term - Inhalation 147 mg/m³ <u>Effects</u> : Systemic
adipohydrazide		DNEL - Workers - Long term - Inhalation 17.5 mg/m³ <u>Effects</u> : Systemic
1,2-benzisothiazol-3(2H)-one		DNEL - General population - Long term - Dermal 0.345 mg/kg bw/day <u>Effects</u> : Systemic
		DNEL - Workers - Long term - Dermal 0.966 mg/kg bw/day <u>Effects</u> : Systemic
		DNEL - General population - Long term - Inhalation 1.2 mg/m ³ <u>Effects</u> : Systemic
		DNEL - Workers - Long term - Inhalation 6.81 mg/m ³

SECTION 8: Exposure controls/personal protection

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) Effects: Systemic

DNEL - General population - Long term - Inhalation 0.02 mg/m³ Effects: Local

DNEL - Workers - Long term - Inhalation 0.02 mg/m³ Effects: Local

DNEL - General population - Short term - Inhalation 0.04 mg/m³ <u>Effects</u>: Local

DNEL - Workers - Short term - Inhalation 0.04 mg/m³ Effects: Local

DNEL - General population - Long term - Oral 0.09 mg/kg bw/day <u>Effects</u>: Systemic

DNEL - General population - Short term - Oral 0.11 mg/kg bw/day <u>Effects</u>: Systemic

PNECs

Not available.

8.2 Exposure controls		
Appropriate engineering controls	Good general ventilation should be sufficient to control worker exposure to airborr contaminants.	
Individual protection measu	<u>es</u>	
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working peri Appropriate techniques should be used to remove potentially contaminated cloth Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.	
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a ris assessment indicates this is necessary to avoid exposure to liquid splashes, mis gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses v side-shields.	sts,
Skin protection		
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard sho be worn at all times when handling chemical products if a risk assessment indica this is necessary.	
	Recommendations : Wear suitable gloves tested to EN374.	
	> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm	
	Not recommended polyvinyl alcohol (PVA) gloves	
Body protection	: Personal protective equipment for the body should be selected based on the tas being performed and the risks involved and should be approved by a specialist before handling this product.	k
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should b approved by a specialist before handling this product.	e

SECTION 8: Exposure controls/personal protection

•	• •
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
	Filter type (spray application): A P
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>	
Physical state	: Liquid.
Colour	: Clear.
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and	:
boiling range	

Ingredient name	°C	°F	Method	
water	100	212		
3-Butoxypropan-2-ol	171	339.8	OECD 103	

Flammability : N	ot available.
------------------	---------------

Lower and upper explosion	: Lower: Not applicable.
limit	Upper: Not applicable.

÷

Flash point

: Closed cup: >100°C (>212°F)

Auto-ignition temperature

Ingredient name	°C	°F	Method
Propylenglycoldimethylether	165	329	
3-Butoxypropan-2-ol	260	500	EU A.15

Decomposition temperature	: Not available.
рН	: 🛿 to 9 [Conc. (% w/w): 100%]
Viscosity	: Not available.
Solubility(ies)	÷
Not available.	
Solubility in water	: Not available.
Partition coefficient: n-octanol/ water	: Not applicable.

2

Vapour pressure

	Vapour Pressure at 20°C		Vapour pressure at 50			
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method
water	17.5	2.3				
3-Butoxypropan-2-ol	1.05	0.14	OECD 104			
Relative density	: Not	available.				
Density	: 1 g/	cm³				
Vapour density	: Not	available.				
Particle characteristics						

Date of previous issue

Date of issue/Date of revision: 14/07/2025DTEKNOCOAT AQUA 1878-63 - HY 0030 CLEAR



SECTION 9: Physical and chemical properties

Median particle size

: Not applicable.

9.2 Other information9.2.1 Information with regard to physical hazard classes

Explosive properties : Not available.

Oxidising properties : Not available.

9.2.2 Other safety characteristics

Not applicable.

SECTION 10: Stability and reactivity

10.1 Reactivity	No specific test data related to reactivity available for this product or its ingr	edients.
10.2 Chemical stability	The product is stable.	
10.3 Possibility of hazardous reactions	Under normal conditions of storage and use, hazardous reactions will not o	ccur.
10.4 Conditions to avoid	No specific data.	
10.5 Incompatible materials	No specific data.	
10.6 Hazardous decomposition products	Under normal conditions of storage and use, hazardous decomposition pro- should not be produced.	ducts

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in	Regulation (EC) No 1272/2008
Acute toxicity	
Product/ingredient name	Result
<mark>β-</mark> Butoxypropan-2-ol	Rabbit - Dermal - LD50 3100 mg/kg
1,2-benzisothiazol-3(2H)-one	Rat - Oral - LD50 1020 mg/kg
reaction mass of: 5-chloro-2-methyl- 4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	Rat - Oral - LD50 53 mg/kg <u>Toxic effects</u> : Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lung, Thorax, or Respiration - Respiratory depression

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
͡ 3 -Butoxypropan-2-ol	N/A	3100	N/A	N/A	N/A
1,2-benzisothiazol-3(2H)-one	450	N/A	N/A	N/A	0.21
reaction mass of: 5-chloro-2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6] (3:1)	53	50	N/A	0.5	N/A

Skin corrosion/irritation

Product/ingredient name

Result

1.2-benzisothiazol-3(2H)-one Human - Skin - Mild irritant Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 % reaction mass of: 5-chloro-2-methyl- 4-hothiazoh-3-one [EC no. 220-239-0] (3:1) Human - Skin - Severe irritant Amount/concentration applied: 0.01 % 200-239-0] (3:1) Conclusion/Summary [Product] : Not available. Ingredient name BFButoxypropan-2-ol Conclusion/Summary Stightly irritating to the skin. Serious eve damage/eve irritation Not available. Conclusion/Summary Stightly irritating to the skin. Serious eve damage/eve irritation Not available. Conclusion/Summary Stightly irritating to the skin. Skin Conclusion/Summary [Product] : Not available. Respiratory corrosion/Irritation Not available. Respiratory corrosion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Gene cell mutagenicity Not available. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Specific target or	3-Butoxypropan-2-ol	Rabbit - Skin - Moderate irritant	
4-sonitazolina-sone [EC no. 247-5007] and 200-2019. Amount/concentration applied: 0.01 % 20-239-6] (3.1) Conclusion/Summary [Product] : Not available. Mignediant name Brotoxypropan-2-ol Signity irritating to the skin. Scricus ove damageleve irritation Not available. Signity irritating to the skin. Conclusion/Summary [Product] : Not available. Signity irritating to the skin. Respiratory corrosion/irritation Not available. Signity irritating to the skin. Skin Conclusion/Summary [Product] : Not available. Signity irritating to the skin. Respiratory corrosion/irritation Not available. Not available. Skin Conclusion/Summary [Product] : Not available. Signity irritating to the skin. Conclusion/Summary [Product] : Not available. Signity irritating to the skin. Gern cell mutagenicity Not available. Not available. Scricuson/Summary [Product] : Not available. Signity irritating to the skin. Mareaulable. Signity irritating to the skin. Mareaulable. Signity irritating to the skin. Mareaulable. Signity irritating to the skin. Scricusion/Summary [Product] : Not available. Signity irritating to the skin. Mareaulable. Signity irritating to the skin. Conclusion/Summary [Product] :	1,2-benzisothiazol-3(2H)-one	Duration of treatment/exposure: 48 ho	ours
Impredient name PEbutoxypropan-2-ol Conclusion/Summary Slightly irritating to the skin. Serious eve damage/eye irritation Not available. Sightly irritating to the skin. Serious eve damage/eye irritation Not available. Sightly irritating to the skin. Respiratory corrosion/irritation Not available. Sightly irritation Not available. Skin Conclusion/Summary [Product] : Not available. Sightly irritation Not available. Skin Conclusion/Summary [Product] : Not available. Sightly irritation Not available. Gern cell mutagenicity Not available. Not available. Conclusion/Summary [Product] : Not available. Sightly irritation Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Sightly irritation Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Sightly irritation Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Sightly irritation Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Sightly irritation Sightly irritation Conclusion/Summary [Product] : Not available. Specific target organ toxicity (repeated exposure) Not available. Sightly irritation Conclusion/Summary [Product] : Not available. Specific target organ toxicity (repeated exposure) Not available. Sightly irritation Conclusion/Summary	4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no.)
PButoxypropan-2-ol Slightly irritating to the skin. Serious eve damage/eye irritation Not available. Scious eve damage/eye irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory corrosion/firritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Scin Conclusion/Summary [Product] : Not available. Gern coll mutagenicity Not available. Not available. Conclusion/Summary [Product] : Not available. Scin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Scin Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Scin Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Scin Conclusion/Summary [Product] : Not available. Specific target organ toxicity (repeated exposure) Not available. Scin Conclusion/Summary [Product] : Not available. Specific target organ toxicity (repeated exposure) Not available. Scin Conclusion/Sum available. Specific target organ toxicity (repeated exposure) Not available. Scin Conclusion/Sum available.	Conclusion/Summary [Product] : Not availab	le.	
Not available. Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available.		-	
Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory Onclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available.			
Not available: Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Gern cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Garcinogenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available.	Conclusion/Summary [Product] : Not availab	le.	
Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available.			
Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available.	Conclusion/Summary [Product] : Not available	e.	
Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available.			
Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Conclusion/Summary [Product] : 1407/2025 Date of previous issue : 06/10/202 Yersior : 2 Yersior : 2 Yersior		e.	
Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16		le.	
Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16			
Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16	Conclusion/Summary [Product] : Not availab	le.	
Reproductive toxicity Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16			
Not available. Conclusion/Summary [Product] : Not available. Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16	Conclusion/Summary [Product] : Not availab	e.	
Specific target organ toxicity (single exposure) Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16			
Not available. Specific target organ toxicity (repeated exposure) Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16	Conclusion/Summary [Product] : Not availab	le.	
Not available. Date of issue/Date of revision : 14/07/2025 Date of previous issue : 06/10/2023 Version : 2 9/16			
•		2	
		f previous issue : 06/10/2023	

SECTION 11: Toxicological information

Aspiration hazard	
Not available.	
Information on likely route	es of exposure
Not available.	
Potential acute health effe	<u>acts</u>
Eye contact	: No known significant effects or critical hazards.
Inhalation	: No known significant effects or critical hazards.
Skin contact	: No known significant effects or critical hazards.
Ingestion	: No known significant effects or critical hazards.
Symptoms related to the	ohysical, chemical and toxicological characteristics
Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.
· · · · · · · · · · · · · · · · · · ·	fects as well as chronic effects from short and long-term exposure
Short term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	s : Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	s : Not available.
Potential chronic health e	<u>ffects</u>
Not available.	
Conclusion/Summary [F	Product] : Not available.
General	: No known significant effects or critical hazards.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
11.2 Information on other h 11.2.1 Endocrine disruptir Not available.	
Conclusion/Summary [F	Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC)

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name 1,2-benzisothiazol-3(2H)-one

Result

Acute - LC50 - Fresh water OECD [Fish, Acute Toxicity Test] Fish - Trout - Onorhynchus Mykiss 1.9 mg/l [96 hours]

Acute - EC50

No. 1907/2006 or Regulation (EC) No 1272/2008.

OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test] Daphnia - Daphnia - Daphnia Magna 3.7 mg/l [48 hours]

:06/10/2023

SECTION 12: Ecological information

Acute - EC50 - Marine water

OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - *Skeletonema Costatum* 0.36 mg/l [72 hours]

Acute - NOEC - Marine water

OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - *Skeletonema Costatum* 0.15 mg/l [72 hours]

Conclusion/Summary [Product] : Not available.

12.2 Persistence and degradability Product/ingredient name

Result

7,2-benzisothiazol-3(2H)-one

EU

24% [28 days]

Conclusion/Summary [Product] : Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
1,2-benzisothiazol-3(2H)-one	-	-	Inherent

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
3-Butoxypropan-2-ol	1.2	-	Low
1,2-benzisothiazol-3(2H)-one	-	3.2	Low

12.4 Mobility in soil

Soil/water partition coefficient

Product/ingredient name	logKoc	Кос
Butoxypropan-2-ol	1.5	28.6002
adipohydrazide	1.7	55.2165
1,2-benzisothiazol-3(2H)-one	1.9	73.142

Results of PMT and vPvM assessment

Product/ingredient name	PMT	Р	Μ	т	vPvM	vP	vM
Butoxypropan-2-ol adipohydrazide 1,2-benzisothiazol-3(2H)-one reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3: 1)	No No No						
Mobility	: Not av	ailable.			<u>.</u>		

Conclusion/Summary

: The product does not meet the criteria to be considered as a PMT or vPvM.

12.5 Results of PBT and vPvB assessment Regulation (EC) No. 1907/2006 [REACH]

Product/ingredient name	PBT	Р	В	Т	vPvB	vP	vB
Butoxypropan-2-ol adipohydrazide 1,2-benzisothiazol-3(2H)-one reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3: 1)	No No No	N/A N/A N/A	N/A N/A No N/A	No No No	N/A N/A No N/A	N/A N/A N/A N/A	N/A N/A No N/A
Regulation (EC) No. 1272/20	08 [CLP]						
Product/ingredient name	PBT	Р	В	т	vPvB	vP	vB
Butoxypropan-2-ol adipohydrazide 1,2-benzisothiazol-3(2H)-one reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3: 1)	No No No	No No No	No No No	No No No	No No No	No No No	No No No

12.6 Endocrine disrupting properties

Not available.

Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods	s	
Product	-	
Methods of disposal	:	The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	:	Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.
European waste catalogue (EWC)	:	080112
Packaging		
Methods of disposal	:	The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	:	This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Date of issue/Date of revision	: 14/07/2025	Date of previous issue	:06/10/2023	Version	:2	12/16
TEKNOCOAT AQUA 1878-63 - H	Y 0030 CLEA	AR		Label No	1225	25

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

: Not relevant/applicable due to nature of the product.

user

14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

13/16

14.7 Maritime transport in bulk according to IMO instruments

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

TEKNOCOAT AQUA 1878-63 -	HY 0030 CLEAR	Label No :	122525
Date of issue/Date of revision	: 14/07/2025 Date of previous issue	: 06/10/2023 Version	:2 13
Seveso Directive			
Persistent Organic Polluta Not listed.	<u>nts</u>		
Not listed.			
Prior Informed Consent (Pl	C) (649/2012/EU)		
Ozone depleting substance Not listed.	<u>95 (EU 2024/590)</u>		
Explosive precursors	: Not applicable.		
Industrial emissions (integrated pollution prevention and control) - Water	: Not listed		
Industrial emissions (integrated pollution prevention and control) - Air	: Not listed		
Other EU regulations			
Labelling	:		
Annex XVII - Restrictions on substances, mixtures and a	the manufacture, placing on the mai rticles	rket and use of certain dangerous	-

SECTION 15: Regulatory information

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety : Not applicable. assessment

SECTION 16: Other information

Indicates information that has changed from previously issued version.

	5 I ,
Abbreviations and	: ATE = Acute Toxicity Estimate
acronyms	CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.
-	1272/2008]
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

Full text of abbreviated H statements

H301	Toxic if swallowed.
H302	Harmful if swallowed.
H310	Fatal in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

Full text of classifications [CLP/GHS]

SECTION 16: Other information

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Skin Corr. 1C	SKIN CORROSION/IRRITATION - Category 1C
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
Date of issue/ Date of	: 14/07/2025
revision	
Date of previous issue	: 06/10/2023
Version	: 2

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.